Abilify and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported only by a few people who take Abilify.

The phase IV clinical study analyzes which people take Abilify and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 84,998 people who have side effects while taking Abilify from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 30, 2022

84,998 people reported to have side effects when taking Abilify.
Among them, 5 people (0.01%) have Gastrointestinal inflammation.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 88,845 Abilify users for its effectiveness, alternative drugs and more.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 759 drugs and 492 conditions by eHealthMe.

Number of Abilify and Gastrointestinal inflammation reports submitted per year:

Could Abilify cause Gastrointestinal inflammation?

Gender of people who have Gastrointestinal inflammation when taking Abilify *:

female: 80 %
male: 20 %

Age of people who have Gastrointestinal inflammation when taking Abilify *:

Common drugs people take besides Abilify *:

Common side effects people have besides Gastrointestinal inflammation *:

Nausea And Vomiting: 3 people, 60.00%
Nausea (feeling of having an urge to vomit): 2 people, 40.00%
Diarrhea: 2 people, 40.00%
Weight Decreased: 1 person, 20.00%
Drug Specific Antibody Present: 1 person, 20.00%
Abdominal Distension: 1 person, 20.00%
Abdominal Pain: 1 person, 20.00%
Bacterial Test Positive: 1 person, 20.00%
Colitis (inflammation of colon): 1 person, 20.00%
Constipation: 1 person, 20.00%

Common conditions people have *:

Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 3 people, 60.00%
Stress And Anxiety: 1 person, 20.00%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 1 person, 20.00%
High Blood Cholesterol: 1 person, 20.00%
Affective Disorder (mental disorder): 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

Related studies

Alternative drugs to, pros and cons of Abilify:

Abilify (88,845 reports)

Gastrointestinal inflammation treatments and more:

Gastrointestinal inflammation (6,885 reports)

COVID vaccines that are related to Gastrointestinal inflammation:

How severe was Gastrointestinal inflammation and when was it recovered:

Gastrointestinal inflammation in Abilify

Expand to all the drugs that have ingredients of aripiprazole:

Gastrointestinal inflammation and drugs with ingredients of aripiprazole

Common drugs associated with Gastrointestinal inflammation:

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.